866-997-4948(US-Canada Toll Free)

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 62 Pages

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2016, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview 8
Therapeutics Development 9
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development 9
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area 10
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication 11
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies 14
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development 22
Ablynx NV 22
Amgen Inc 23
Apogenix GmbH 24
Bristol-Myers Squibb Company 25
Five Prime Therapeutics Inc 26
Incyte Corp 27
MedImmune LLC 28
Merck & Co Inc 29
Novartis AG 30
OncoMed Pharmaceuticals Inc 31
Regeneron Pharmaceuticals Inc 32
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles 33
AMG-228 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BMS-986156 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
FPA-154 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GWN-323 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
INCAGN-1876 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LKZ-145 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MEDI-1873 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
MK-1248 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
MK-4166 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
TRX-518 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases 50
Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist 50
Nov 11, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting Demonstrating Potent Anti-Tumor Activity with Novel Tetravalent Anti-GITR Antibody 50
Nov 03, 2016: Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody 51
Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors 51
Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting 52
Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016 52
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 53
Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody 54
Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference 54
Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses 55
Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518 56
Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer 57
Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518 58
Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer 59
Oct 21, 2008: Laureate To Manufacture Tolerxs TRX518 Antibody 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Ablynx NV, H2 2016 22
Pipeline by Amgen Inc, H2 2016 23
Pipeline by Apogenix GmbH, H2 2016 24
Pipeline by Bristol-Myers Squibb Company, H2 2016 25
Pipeline by Five Prime Therapeutics Inc, H2 2016 26
Pipeline by Incyte Corp, H2 2016 27
Pipeline by MedImmune LLC, H2 2016 28
Pipeline by Merck & Co Inc, H2 2016 29
Pipeline by Novartis AG, H2 2016 30
Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 31
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 32

List of Figures
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Top 10 Indication, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *